---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-026840"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2022-09-26T23:59:59+00:00"
generated_at: "2026-06-23T07:35:26.592424+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics amends employment agreements and adopts bonus plan

## Summary
- New employment agreements set salaries: CEO $690k, GC $394.8k, SVP $366.8k; bonus targets 55%, 40%, 35% respectively.
- Termination benefits enhanced: CEO receives 12 months salary + 100% bonus (18 months + 150% on change of control); others receive 9 months + pro-rata (12 months + 100% on change of control).
- New Executive Performance Incentive Bonus Plan adopted; bonuses tied to financial, clinical, and operational goals determined by Compensation Committee.

## SEC filing metadata
- accession: 0001493152-22-026840
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2022-09-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000149315222026840/0001493152-22-026840-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000149315222026840/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-026840
- JSON: https://secwatch.observer/filing/0001493152-22-026840.json
- Plain text: https://secwatch.observer/filing/0001493152-22-026840.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.